2.44

0.83% 0.02

Xenetic Biosciences Inc (XBIO)

Overview News Price History Financials Discussions Forecast Stock Split

Xenetic Biosciences Inc stock is traded at $2.44, with a volume of 21,674. It is up +0.83% in the last 24 hours and down -7.58% over the past month. Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Previous Close:

$2.42

Open:

$2.42

24h Volume:

21,674

Relative Volume:

0.03

Market Cap:

$5.59M

Revenue:

$2.54M

Net Income/Loss:

$-4.13M

P/E Ratio:

-0.8873

EPS:

-2.75

Net Cash Flow:

$-4.11M

1W Performance:

-3.56%

1M Performance:

-7.58%

6M Performance:

-24.69%

1Y Performance:

-41.90%

1-Day Range:

$2.41

$2.53

1-Week Range:

$2.31

$2.6398

52-Week Range:

$2.20

$13.93

Xenetic Biosciences Inc Stock (XBIO) Company Profile

Name

Xenetic Biosciences Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

781-778-7720

Address

945 CONCORD ST., FRAMINGHAM, MA

Employee

Twitter

@XeneticBio

Next Earnings Date

2024-11-07

Latest SEC Filings

XBIO's Discussions on Twitter

Compare XBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XBIO Xenetic Biosciences Inc	2.44	5.54M	2.54M	-4.13M	-4.11M	-2.75
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-20	Initiated	Maxim Group	Buy

Xenetic Biosciences Inc Stock (XBIO) Latest News

Dec 13, 2025

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Green Bay Press-Gazette

Dec 13, 2025

Value Recap: Will Xenetic Biosciences Inc stock attract more institutional investorsMarket Performance Report & Verified Technical Signals - moha.gov.vn

Dec 13, 2025

Dec 12, 2025

Xenetic Biosciences adjourns 2025 annual meeting - MSN

Dec 12, 2025

Dec 11, 2025

Xenetic Biosciences Adjourns 2025 Annual Meeting - TipRanks

Dec 11, 2025

Xenetic Biosciences (NASDAQ: XBIO) Resets 2025 Annual Meeting to Jan. 8, 2026 - Stock Titan

Dec 11, 2025

Dec 08, 2025

Can Xenetic Biosciences Stock Recover If Markets Fall? - Trefis

Dec 08, 2025

Dec 07, 2025

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Morris County NJ News | Daily Record

Dec 07, 2025

EBITDA per share of Xenetic Biosciences, Inc. – BER:3XB0 - TradingView

Dec 07, 2025

Dec 06, 2025

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - SouthCoastToday.com

Dec 06, 2025

Dec 05, 2025

Will Xenetic Biosciences Inc. stock keep outperforming rivals2025 Buyback Activity & Risk Controlled Stock Alerts - Newser

Dec 05, 2025

Published on: 2025-12-05 14:51:47 - moha.gov.vn

Dec 05, 2025

Dec 04, 2025

Is Xenetic Biosciences Inc. (3XB0) stock a top hedge fund pick2025 Top Gainers & Reliable Volume Spike Trade Alerts - Newser

Dec 04, 2025

Is Xenetic Biosciences Inc. (3XB0) stock a buy for dividend portfoliosWeekly Stock Report & Real-Time Sentiment Analysis - Newser

Dec 04, 2025

Dec 03, 2025